抗血小板药物抵抗的研究进展  

Research Advances in Antiplatelet Resistance

作　　者：谢媛[1] 马向华[1] 

机构地区：[1]南京医科大学第一附属医院内分泌科,南京210029

出　　处：《医学综述》2012年第20期3364-3367,共4页Medical Recapitulate

摘　　要：抗血小板药物从20世纪60年代问世一直应用至今,是治疗心血管疾病、预防血栓事件的主要手段。随着药物的广泛应用,人们发现,部分接受抗血小板药物治疗的患者仍然发生血栓事件,被称为"抗血小板药物抵抗"。这一现象与药物的剂量、药物间的相互作用、基因的多态性、基础血小板的反应性、药物吸收的个体差异、患者依从性等多个因素密切相关。联合使用药物或加大剂量是目前最主要应对药物抵抗的措施,但也增加了出血并发症的危险。Antiplatelet agents have been the principle therapy in cardiovascular disease and prevention of thrombotic events so far since it came out in 1960s.Along with the wide application of the drug,it is found that thrombotic event still occurs in some patients who receive the therapy,which is called antiplatelet resistance.Drug doses,drug interactions,gene polymorphism,baseline platelet activation,individual drug absorption difference and metabolism,and patient compliance and others were discovered to be the close correlation factors.Using a combination of drugs or increasing drug dosage is known to be the main solution,however,it also increases the risk of bleeding complications.

关 键 词：抗血小板 阿司匹林 氯吡格雷 抵抗 血栓 

分 类 号：R543.5[医药卫生—心血管疾病] R969[医药卫生—内科学]